Mesulergine (CU32-085) in the treatment of Parkinson's disease

Ronald Pfeiffer, K. Wilken, C. Glaeske

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Twenty patients with Parkinson's disease were treated with the 8-α-ergoline derivative mesulergine. Participants were divided into two groups, and over a nine-week period, mesulergine dosage was increased to a maximum of either 10 or 20 mg daily. During this time levodopa-carbidopa (LD-CD) dosage was reduced and treatment was discontinued if possible. The dosage of LD-CD was reduced 75% in the 10 mg group and 74% in the 20 mg group. Patients in the low-dose group maintained their functional status and showed improvement in postural stability. Patients in the high-dose group showed improvement in each of the cardinal signs of parkinsonism. Adverse effects were generally mild and infrequent. Many adverse effects induced by LD-CD diminished or resolved. Our results suggest that mesulergine can be valuable in the management of Parkinson's disease, particularly in those individuals experiencing dose-limiting adverse effects from LD-CD.

Original languageEnglish (US)
Pages (from-to)334-336
Number of pages3
JournalAnnals of Neurology
Volume17
Issue number4
StatePublished - 1985
Externally publishedYes

Fingerprint

Parkinson Disease
Ergolines
Parkinsonian Disorders
Therapeutics
mesulergine
levodopa drug combination carbidopa

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Mesulergine (CU32-085) in the treatment of Parkinson's disease. / Pfeiffer, Ronald; Wilken, K.; Glaeske, C.

In: Annals of Neurology, Vol. 17, No. 4, 1985, p. 334-336.

Research output: Contribution to journalArticle

Pfeiffer, R, Wilken, K & Glaeske, C 1985, 'Mesulergine (CU32-085) in the treatment of Parkinson's disease', Annals of Neurology, vol. 17, no. 4, pp. 334-336.
Pfeiffer, Ronald ; Wilken, K. ; Glaeske, C. / Mesulergine (CU32-085) in the treatment of Parkinson's disease. In: Annals of Neurology. 1985 ; Vol. 17, No. 4. pp. 334-336.
@article{632948df34b443e7ad2b6f4c068457cd,
title = "Mesulergine (CU32-085) in the treatment of Parkinson's disease",
abstract = "Twenty patients with Parkinson's disease were treated with the 8-α-ergoline derivative mesulergine. Participants were divided into two groups, and over a nine-week period, mesulergine dosage was increased to a maximum of either 10 or 20 mg daily. During this time levodopa-carbidopa (LD-CD) dosage was reduced and treatment was discontinued if possible. The dosage of LD-CD was reduced 75{\%} in the 10 mg group and 74{\%} in the 20 mg group. Patients in the low-dose group maintained their functional status and showed improvement in postural stability. Patients in the high-dose group showed improvement in each of the cardinal signs of parkinsonism. Adverse effects were generally mild and infrequent. Many adverse effects induced by LD-CD diminished or resolved. Our results suggest that mesulergine can be valuable in the management of Parkinson's disease, particularly in those individuals experiencing dose-limiting adverse effects from LD-CD.",
author = "Ronald Pfeiffer and K. Wilken and C. Glaeske",
year = "1985",
language = "English (US)",
volume = "17",
pages = "334--336",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Mesulergine (CU32-085) in the treatment of Parkinson's disease

AU - Pfeiffer, Ronald

AU - Wilken, K.

AU - Glaeske, C.

PY - 1985

Y1 - 1985

N2 - Twenty patients with Parkinson's disease were treated with the 8-α-ergoline derivative mesulergine. Participants were divided into two groups, and over a nine-week period, mesulergine dosage was increased to a maximum of either 10 or 20 mg daily. During this time levodopa-carbidopa (LD-CD) dosage was reduced and treatment was discontinued if possible. The dosage of LD-CD was reduced 75% in the 10 mg group and 74% in the 20 mg group. Patients in the low-dose group maintained their functional status and showed improvement in postural stability. Patients in the high-dose group showed improvement in each of the cardinal signs of parkinsonism. Adverse effects were generally mild and infrequent. Many adverse effects induced by LD-CD diminished or resolved. Our results suggest that mesulergine can be valuable in the management of Parkinson's disease, particularly in those individuals experiencing dose-limiting adverse effects from LD-CD.

AB - Twenty patients with Parkinson's disease were treated with the 8-α-ergoline derivative mesulergine. Participants were divided into two groups, and over a nine-week period, mesulergine dosage was increased to a maximum of either 10 or 20 mg daily. During this time levodopa-carbidopa (LD-CD) dosage was reduced and treatment was discontinued if possible. The dosage of LD-CD was reduced 75% in the 10 mg group and 74% in the 20 mg group. Patients in the low-dose group maintained their functional status and showed improvement in postural stability. Patients in the high-dose group showed improvement in each of the cardinal signs of parkinsonism. Adverse effects were generally mild and infrequent. Many adverse effects induced by LD-CD diminished or resolved. Our results suggest that mesulergine can be valuable in the management of Parkinson's disease, particularly in those individuals experiencing dose-limiting adverse effects from LD-CD.

UR - http://www.scopus.com/inward/record.url?scp=0021832018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021832018&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 334

EP - 336

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 4

ER -